ArticleDiscover oncology2026
A systematic scoping review of the molecular pathogenesis of digestive system cancers (2013-2025).
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digestive system cancers (DSCs) remain among the most prevalent and lethal malignancies worldwide, accounting for more than a quarter of cancer diagnoses and a third of cancer deaths. Advances in next-generation sequencing (NGS) have accelerated discovery of genetic, epigenetic, and transcriptomic alterations, yet an integrated overview across DSCs is lacking. This scoping review synthesized 57 studies published between 2013 and 2025 from PubMed, Scopus, and Web of Science. Colorectal and gastric cancers were most frequently represented, while oesophageal, pancreatic, and rare subtypes such as gallbladder and ampullary cancers were under-studied. Recurrent alterations in TP53, KRAS, PIK3CA, and CDKN2A were identified, alongside mismatch repair deficiency and microsatellite instability in colorectal and gastric cancers. Emerging evidence from recently published studies further highlights the contribution of germline alterations and increased molecular heterogeneity in selected DSC subtypes. Epigenetic dysregulation and recent applications of single-cell and spatial transcriptomics highlighted tumour heterogeneity. Despite progress, evidence remains uneven across cancer types, with limited exploration of germline variants beyond colorectal, pancreatic, and select liver cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.